Abstract
Nonalcoholic fatty liver disease (NAFLD) is among the most common causes of chronic liver disease in the westernized world and now represents a worldwide public health problem. NAFLD encompasses a broad spectrum of conditions, ranging from simple steatosis (nonalcoholic fatty liver) to nonalcoholic steatohepatitis (NASH). The latter is recognized as a potentially progressive disease that could lead to cirrhosis, liver failure, and hepatocellular carcinoma. The recent rise in obesity likely explains the NAFLD epidemic worldwide. Recognition of the importance of NAFLD and its strong association with metabolic syndrome has stimulated interest in its putative role in the development of cardiovascular disease (CVD). Recently, accumulating evidence suggests that NAFLD is associated with a significant greater overall mortality, as well as with increased prevalence of CVD, both of which are independent of classical atherosclerotic risk factors. Furthermore, observation studies of natural history of NAFLD have shown that increased age-related mortality of NAFLD patients is attributable to CVD and liver-related diseases such as liver failure and hepatocellular carcinoma. In this paper, we review clinical data to support a strong association between NAFLD and CVD, and discuss possible underlying mechanisms for accelerated atherosclerosis in NAFLD.
Keywords: Nonalcoholic fatty liver disease, cardiovascular disease, atherosclerosis.
Current Pharmaceutical Design
Title:Nonalcoholic Fatty Liver Disease and Cardiovascular Disease
Volume: 20 Issue: 14
Author(s): Hideyuki Hyogo, Kazuaki Chayama and Sho-ichi Yamagishi
Affiliation:
Keywords: Nonalcoholic fatty liver disease, cardiovascular disease, atherosclerosis.
Abstract: Nonalcoholic fatty liver disease (NAFLD) is among the most common causes of chronic liver disease in the westernized world and now represents a worldwide public health problem. NAFLD encompasses a broad spectrum of conditions, ranging from simple steatosis (nonalcoholic fatty liver) to nonalcoholic steatohepatitis (NASH). The latter is recognized as a potentially progressive disease that could lead to cirrhosis, liver failure, and hepatocellular carcinoma. The recent rise in obesity likely explains the NAFLD epidemic worldwide. Recognition of the importance of NAFLD and its strong association with metabolic syndrome has stimulated interest in its putative role in the development of cardiovascular disease (CVD). Recently, accumulating evidence suggests that NAFLD is associated with a significant greater overall mortality, as well as with increased prevalence of CVD, both of which are independent of classical atherosclerotic risk factors. Furthermore, observation studies of natural history of NAFLD have shown that increased age-related mortality of NAFLD patients is attributable to CVD and liver-related diseases such as liver failure and hepatocellular carcinoma. In this paper, we review clinical data to support a strong association between NAFLD and CVD, and discuss possible underlying mechanisms for accelerated atherosclerosis in NAFLD.
Export Options
About this article
Cite this article as:
Hyogo Hideyuki, Chayama Kazuaki and Yamagishi Sho-ichi, Nonalcoholic Fatty Liver Disease and Cardiovascular Disease, Current Pharmaceutical Design 2014; 20 (14) . https://dx.doi.org/10.2174/13816128113199990476
DOI https://dx.doi.org/10.2174/13816128113199990476 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Heat Shock Proteins: Therapeutic Perspectives in Inflammatory Disorders
Recent Patents on Inflammation & Allergy Drug Discovery Prolyl Oligopeptidase: A Rising Star on the Stage of Neuroinflammation Research
CNS & Neurological Disorders - Drug Targets CD93: Recent Advances and Implications in Disease
Current Drug Targets New Concept of Vascular Calcification and Metabolism
Current Vascular Pharmacology Prophylaxis of Cancer
Current Cancer Therapy Reviews Antioxidants Suppress Th1-Type Immune Response In Vitro
Drug Metabolism Letters Mesenchymal Stromal Cell Therapy for Cardio Renal Disorders
Current Pharmaceutical Design Antioxidants as a Potential Preventive and Therapeutic Strategy for Cadmium
Current Drug Targets Candidate Circulating Biomarkers for the Cardiovascular Disease Continuum
Current Pharmaceutical Design Recent Patents on Cardiovascular Stem Cells
Recent Patents on Cardiovascular Drug Discovery Increasing Neurogenesis with Fluoxetine, Simvastatin and Ascorbic Acid Leads to Functional Recovery in Ischemic Stroke
Recent Patents on Drug Delivery & Formulation Metabolomics of Serum Peptides
Protein & Peptide Letters Mental Health Patients at High Risk for Obesity, Type 2 Diabetes, and Cardiovascular Disease: An Australian Perspective
Current Hypertension Reviews Toll-like Receptors and Diabetes Complications: Recent Advances
Current Diabetes Reviews Editorial (Thematic Issues: Autoimmunity and Autoinflammation: Cardiovascular Drug Targets and Design)
Current Pharmaceutical Design Coronary Atherosclerotic Disease Burden: An Emerging Endpoint in Progression / Regression Studies Using Intravascular Ultrasound
Current Drug Targets - Cardiovascular & Hematological Disorders Adipose Tissue as a Regulator of Energy Balance
Current Drug Targets Anti-Inflammatory Agents from Plants: Progress and Potential
Current Medicinal Chemistry Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Inhibitors in the Treatment of Hypercholesterolemia and other Pathologies
Current Pharmaceutical Design Basis for the Application of Analytical Models of the Bloch NMR Flow Equations for Functional Magnetic Resonance Imaging (fMRI): A Review
Recent Patents on Medical Imaging